---
schema_version: "secwatch.filing_event.v1"
accession: "0001104659-24-028788"
form_type: "8-K"
ticker: "NRXP"
cik: "0001719406"
company_name: "NRX Pharmaceuticals, Inc."
filed_at: "2024-02-28T23:59:59+00:00"
generated_at: "2026-06-05T09:07:08.657357+00:00"
event_type: "other_material"
sentiment: "neutral"
materiality_score: 0.6
calibrated_materiality_score: 0.6
confidence: "high"
source: SEC EDGAR
---

# NRx Pharmaceuticals prices $1.5M public offering of 5M shares at $0.30 per share

## Summary
- Underwritten public offering of 5,000,000 shares of common stock at $0.30/share, gross proceeds approx. $1.5 million.
- EF Hutton LLC sole book-runner; underwriters have 45-day option for up to 750,000 additional shares.
- Proceeds for working capital and general corporate purposes; may repay convertible note to Streeterville Capital.
- Underwriter's warrant issued for up to 250,000 shares at $0.33/share, exercisable after 6 months for 5 years.
- Offering closed Feb 28, 2024; 90-day lock-up for directors, officers, and company.

## SEC filing metadata
- accession: 0001104659-24-028788
- form_type: 8-K
- ticker: NRXP
- cik: 0001719406
- company_name: NRX Pharmaceuticals, Inc.
- filed_at: 2024-02-28T23:59:59+00:00
- event_type: other_material
- sentiment: neutral
- materiality_score: 0.6
- calibrated_materiality_score: 0.6
- confidence: high
- sec_items: 1.01, 3.02, 8.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1719406/000110465924028788/0001104659-24-028788-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1719406/000110465924028788/tm247473d1_8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001104659-24-028788
- JSON: https://secwatch.observer/filing/0001104659-24-028788.json
- Plain text: https://secwatch.observer/filing/0001104659-24-028788.txt

## Key facts
- Material Agreements
  NRX Pharmaceuticals, Inc. entered into Underwriting Agreement with EF Hutton LLC (effective 2024-02-27).
  - Action: entry
  - Agreement: underwriting
  - Counterparty: EF Hutton LLC
  - Effective: 2024-02-27
  source text: On February 27, 2024, NRx Pharmaceuticals, Inc. (the " Company ") entered into an underwriting agreement (the " Underwriting Agreement ") with EF Hutton LLC (the " Representative "), as the representative of the several underwriters named therein (the " Underwriters "), relating to an underwritten public offering (the " Offering ") of 5,000,000 shares (the " Shares ") of the Company’s common stock, par value $0.001 per share (" Common Stock ").
  evidence_url: https://www.sec.gov/Archives/edgar/data/1719406/000110465924028788/0001104659-24-028788-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.